COSCIENS Biopharma (CSCI) Competitors $2.50 -0.29 (-10.39%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends CSCI vs. GANX, RLYB, QTTB, SCYX, XLO, CLNN, GRCE, LEXX, VYNE, and ATNMShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Gain Therapeutics (GANX), Rallybio (RLYB), Q32 Bio (QTTB), SCYNEXIS (SCYX), Xilio Therapeutics (XLO), Clene (CLNN), Grace Therapeutics (GRCE), Lexaria Bioscience (LEXX), VYNE Therapeutics (VYNE), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical preparations" industry. COSCIENS Biopharma vs. Gain Therapeutics Rallybio Q32 Bio SCYNEXIS Xilio Therapeutics Clene Grace Therapeutics Lexaria Bioscience VYNE Therapeutics Actinium Pharmaceuticals COSCIENS Biopharma (NASDAQ:CSCI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Does the media favor CSCI or GANX? In the previous week, COSCIENS Biopharma's average media sentiment score of 0.00 equaled Gain Therapeutics'average media sentiment score. Company Overall Sentiment COSCIENS Biopharma Neutral Gain Therapeutics Neutral Which has more volatility & risk, CSCI or GANX? COSCIENS Biopharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Which has preferable earnings and valuation, CSCI or GANX? COSCIENS Biopharma has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$7.60M1.24-$16.55M-$11.87-0.21Gain Therapeutics$50K827.58-$22.27M-$1.10-1.42 Do institutionals and insiders believe in CSCI or GANX? 0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by insiders. Comparatively, 11.7% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CSCI or GANX more profitable? Gain Therapeutics has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. COSCIENS Biopharma's return on equity of -95.93% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-428.43% -95.93% -45.66% Gain Therapeutics N/A -203.91%-128.05% Do analysts recommend CSCI or GANX? Gain Therapeutics has a consensus target price of $7.25, indicating a potential upside of 364.74%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community favor CSCI or GANX? Gain Therapeutics received 34 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformCOSCIENS BiopharmaN/AN/AGain TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% SummaryGain Therapeutics beats COSCIENS Biopharma on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.2110.5990.1317.19Price / Sales1.24196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.175.094.784.78Net Income-$16.55M$151.83M$120.31M$225.60M7 Day Performance-13.79%-2.14%-1.92%-1.23%1 Month Performance-16.94%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$2.50-10.4%N/AN/A$9.40M$7.60M-0.21N/AGap DownGANXGain Therapeutics2.6702 of 5 stars$1.64+0.3%$7.25+343.2%-37.6%$43.39M$50,000.00-1.4820RLYBRallybio2.6942 of 5 stars$1.03-4.6%$9.75+846.6%-63.6%$42.74MN/A-0.6740QTTBQ32 Bio2.8291 of 5 stars$3.46-6.5%$29.86+762.9%N/A$42.15M$-6,651,000.00-0.2439High Trading VolumeSCYXSCYNEXIS0.8192 of 5 stars$1.11-2.6%N/A-46.5%$42.12M$8.57M-1.5460Gap DownXLOXilio Therapeutics2.7966 of 5 stars$0.92-5.6%$4.00+337.2%+140.9%$40.22MN/A-0.5473News CoverageGap UpCLNNClene3.7378 of 5 stars$4.77-3.6%$55.25+1,058.3%-30.2%$39.88M$650,000.00-0.94100Analyst ForecastNews CoverageGRCEGrace TherapeuticsN/A$3.86+7.8%N/AN/A$39.14MN/A-3.54N/APositive NewsLEXXLexaria Bioscience3.1533 of 5 stars$2.22-0.9%$11.00+395.5%+66.4%$38.75M$464,278.00-4.777VYNEVYNE Therapeutics2.6613 of 5 stars$2.60+1.6%$6.88+164.4%-1.6%$38.35M$493,000.00-2.9830News CoverageATNMActinium Pharmaceuticals1.2415 of 5 stars$1.23-0.4%$7.40+504.1%N/A$38.22M$81,000.00-0.8849 Related Companies and Tools Related Companies GANX Competitors RLYB Competitors QTTB Competitors SCYX Competitors XLO Competitors CLNN Competitors GRCE Competitors LEXX Competitors VYNE Competitors ATNM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CSCI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
